Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
APUS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 11, 2026
Report Source: 2025 Annual Report
Apimeds Pharmaceuticals US Inc. Stock Analysis APUS
United States Health Care Nano Cap Report: Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Read More Apimeds Pharmaceuticals US Inc (APUS) Chart
Key Statistics of Apimeds Pharmaceuticals US Inc (APUS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.99Volume
37.97KP/E Ratio (TTM)
-52 Week Range
Market Cap
17.61MAvg. Volume
46.52KDividend Yield
-Financial Metrics & Statements of Apimeds Pharmaceuticals US Inc (APUS)
FAQ's for Apimeds Pharmaceuticals US Inc (APUS)
- According to Musaffa’s Shariah screening methodology, Apimeds Pharmaceuticals US Inc (APUS) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Apimeds Pharmaceuticals US Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Apimeds Pharmaceuticals US Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Apimeds Pharmaceuticals US Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Apimeds Pharmaceuticals US Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Apimeds Pharmaceuticals US Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.